unable to take drugs by mouth history of positive confirmed covid-19 infection within past 3 months involved in any covid-19 vaccine clinical trial patients with suspected concomitant bacterial, fungal infections, concurrent congestive heart failure prior to initiation of study drug known case of liver disease (any severity) alcohol intake more than recommended (2 drinks or more in a day for men and 1 drink or more in a day for women) mal-absorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others). pregnant or nursing/breastfeeding women or women planning for pregnancy. female patients who cannot consent to contraceptive use (any method) from the start of ip administration to 7 days after the second dose of ip administration male patients whose partner cannot agree to use the contraception method as in 9) patients with a history of gout or on treatment for gout or hyperuricemia patients receiving immunosuppressant patients who have previously received ivermectin. patients who are not able to provide written consent. other patients judged ineligible by the principal investigator or sub-investigator

unable to take drugs by mouth history of positive confirmed covid-19 infection within past 3 months involved in any covid-19 vaccine clinical trial patients with suspected concomitant bacterial, fungal infections, concurrent congestive heart failure prior to initiation of study drug known case of liver disease (any severity) alcohol intake more than recommended (2 drinks or more in a day for men and 1 drink or more in a day for women) mal-absorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others). pregnant or nursing/breastfeeding women or women planning for pregnancy. female patients who cannot consent to contraceptive use (any method) from the start of ip administration to 7 days after the second dose of ip administration male patients whose partner cannot agree to use the contraception method as in 9) patients with a history of gout or on treatment for gout or hyperuricemia patients receiving immunosuppressant patients who have previously received ivermectin. patients who are not able to provide written consent. other patients judged ineligible by the principal investigator or sub-investigator